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ABSTRACT 27 
The HER-2 oncogene is a major target for the immunotherapy of breast cancer. Following up to the 28 
therapeutic success achieved with Her-2-targeting monoclonal antibodies, immune-prophylactic 29 
approaches directed against Her-2 have also been investigated taking into account, and trying to 30 
overcome, Her-2 self-tolerance. Perhaps due to safety (and efficacy) concerns, the least explored anti-31 
Her-2 active immunization strategy so far has been the one relying on viral-vectored vaccine 32 
formulations. Taking advantage of the favorable properties of bovine herpesvirus 4 (BoHV-4) in terms 33 
of safety and ease of manipulation as well as its previously documented ability to transduce and confer 34 
immunogenicity to heterologous antigens, we tested the ability of different recombinant HER-2-35 
BoHV-4 immunogens to break tolerance and elicit a protective, anti-mammary tumor antibody 36 
response in HER-2 transgenic BALB-neuT mice. All the tested constructs expressed the HER-2 37 
transgenes at high levels and elicited significant cellular immune responses in BALB/c mice upon 38 
administration via either DNA vaccination or viral infection. In BALB-neuT mice, instead, only  the 39 
viral construct expressing the membrane-bound chimeric form of Her-2 protein (BoHV-4-RHuT-gD) 40 
elicited a humoral immune response that was more intense and earlier-appearing than that induced by 41 
DNA vaccination. In keeping with this observation, two administrations of BoHV-4-RHuT-gD 42 
effectively protected BALB-neuT mice from tumor formation, with 50% of vaccinated animals tumor-43 
free after 30 weeks from immunization compared to 100% of animals exhibiting at least one palpable 44 
tumor in the case of animals vaccinated with the other BoHV-4-HER-2 constructs. 45 
 46 
Keywords: Her-2 oncogene, HER-2 immunogens, BoHV-4-based vector, recombinant BoHV-4s, 47 
BALB-neuT mice, vaccination. 48 
 49 
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Abbreviations: HER-2, epidermal growth factor receptor 2; TK, tyrosine kinase; ATP, adenosine 52 
triphosphate; BoHV-4, bovine herpesvirus 4; HSV-1, herpes simplex virus 1; IgG, immunoglobulin G; 53 
Fc, crystallizable fragment; IFN-γ, interferon gamma; HEK, human embryo kidney; BEK, bovine 54 
embryo kidney; gD, glycoprotein G; DMEM, Dulbecco’s modified eagle medium; EMEM, Eagle’s 55 
minimal essential medium; TCID50, tissue culture infectious dose 50; M.O.I., multiplicity of infection; 56 
BSA, bovine serum albumin; ELISPOT, enzyme linked immune-spot; PBS, phosphate buffer saline; 57 
BAC, bacteria artificial chromosome; RPMI, Roswell Park Memorial Institute medium;  PCR, 58 
polymerase chain reaction; PEI, polyethylenimine; FBS, fetal bovine serum; LB, Luria Bertani’s 59 
medium; CPE, cytopathic effect; CFSE, carboxyfluorescein-diacetate-succinimidyl ester. SEM, standard 60 
error mean; SFU, spot forming units; SPC, spot-forming cells. 61 
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INTRODUCTION 63 
Despite the significant therapeutic improvements achieved in the last decades, breast cancer remains 64 
the most important, women-affecting, solid neoplasm worldwide 1. Overexpression of the epidermal 65 
growth factor receptor 2 (HER-2) oncogene - mainly due to gene amplification-based mechanisms 2, 3 66 
occurs in ~15-25% breast cancers, where it has been consistently associated with metastatization 67 
propensity, poor prognosis and reduced survival 4. 68 
Her-2 is a four transmembrane domain tyrosine kinase (TK) receptor. Although it is structurally and 69 
functionally well characterized, its specific ligand is still unknown. Her-2 homo/hetero dimerization 70 
induces TK domain phosphorylation, thus triggering the activation of multiple signal transduction 71 
pathways 5-7. Among these pathways, those centered on the Ras/Raf mitogen-activated protein kinase 72 
and the phosphatidil-inositole-3-kinase are the best characterized. Their deregulated activation is 73 
causally involved in cancerous phenotype development and results in altered cellular growth/division, 74 
differentiation and adhesion properties 5-7. For these reasons, Her-2 and its associated pathways are 75 
major clinical therapeutic targets. At present, two main classes of molecules are employed in the clinic 76 
to target Her-2. The first is represented by humanized monoclonal antibodies (Trastuzumab and 77 
Pertuzumab), that by targeting the extracellular portion of the receptor, interfere with Her-2 78 
dimerization thus inducing receptor endocytosis and degradation 8, 9. Importantly, these antibodies can 79 
also activate antibody- and complement-mediated cellular cytotoxicity 10. The second class of 80 
therapeutics is composed of synthetic small-molecules that interact with the ATP-binding site of the 81 
intracellular TK domain of Her-2 and block receptor phosphorylation/activation, thus preventing 82 
downstream signaling events 1, 11. Of note, Trastuzumab and Her-2 TK domain inhibitors have been 83 
shown to act synergistically thus paving the way to their combined therapeutic use also in association 84 
with traditional endocrine, chemo and radiation therapies 1.  85 
Prompted by the effectiveness of passive immunization relying on anti-Her-2 antibodies, immune-86 
prophylactic, active immunization approaches directed against Her-2 have also been extensively 87 
explored in preclinical models of mammary cancer 12, 13. However, since Her-2 is a self-tolerated antigen 88 
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(Ambrosino et al., 2006), a major hurdle for these approaches has been the breaking of central and 89 
peripheral tolerance 14-17. Several ways to overcome this problem have been developed 18-20, including 90 
vaccination with hybrid DNA constructs coding for chimeric rat/human Her-2 proteins 21-23. 91 
A very little explored, but potentially promising tolerance breaking/immunization strategy relies on the 92 
use of viral-vectored vaccine formulations. In fact, viral vectors can deliver the antigen directly into 93 
host cells, thus leading to high-level transgene cellular expression. Key properties of an effective, and 94 
potentially translatable, viral vector are safety, the ability to properly present the expressed antigen to 95 
the immune system and to remain within host cells long enough to stimulate an effective response. A 96 
viral vector apparently meeting these criteria, including ease of manipulation (with the possibility to 97 
insert up to 30 kb of foreign DNA) and the ability to confer strong immunogenicity to heterologous 98 
antigens, is bovine herpesvirus 4 (BoHV-4). Cattle is the natural host of this virus, but BoHV-4 isolates 99 
have been retrieved from other animal species as well. In vitro, BoHV-4 is able to replicate in primary 100 
cultures and cell lines from a variety of animal species 24-30. Experimental infection of many non-natural 101 
hosts [mice 28, rats 31, rabbits 27, sheep 25, swine 32 and goats 30 as well as ex vivo tissue explants from non-102 
human primates has been documented (personal communication), suggesting that BoHV-4 is most 103 
likely also competent for human cell transduction. In infected mice, BoHV-4 behaves as a replication-104 
incompetent virus 33 that preferentially localizes to cells of the monocyte/macrophage lineage 34. At 105 
variance with other gamma-herpesviruses, no evidence for growth-transformation, nor any virus-106 
associated pathology has been reported for BoHV-4 so far. In fact, recombinant BoHV-4s expressing 107 
immune-dominant antigens from different pathogens have been successfully employed to immunize 108 
genetically modified mice without any detrimental effect, overt clinical sign or pathology correlated to 109 
viral vector inoculation 28. Furthermore, a BoHV-4-based vector armed with a Herpes Simplex virus-1 110 
thymidine kinase (HSV-1-TK) gene displayed enhanced oncolytic properties in immune-competent 111 
orthotopic syngenic mouse and rat glioma models 29. 112 
In view of all these favorable properties, and good potential for clinical translation, we set out to test 113 
BoHV-4 as a HER-2 expression carrier and novel immuno-prophylactic agent against Her-2+ mammary 114 
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cancer. Since vaccine delivery and cellular localization of vaccine-encoded antigens are key factors in 115 
modulating the induced immune responses, we assembled different recombinant HER-2-BoHV-4 viral 116 
vectors and tested their immunogenicity as well as cancer prevention capacity. The recombinant vector 117 
expressing the membrane-bound form of a hybrid, rat-human Her-2 antigen was found to be the only 118 
one capable of eliciting high anti-Her-2 antibody titers in immune-tolerant, rat HER2 transgenic 119 
(BALB-neuT) mice and to afford strong protection against autochthonous Her-2+ mammary cancer 120 
development in these animals. 121 
 122 
  123 
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RESULTS 124 
Design and expression of different Her-2 chimeric proteins 125 
Before generating BoHV-4-based vectors expressing specific portions of HER-2 oncogene, three 126 
optimized ORFs coding for different HER-2 derived chimeric fragments were customized taking into 127 
account antigen subcellular localization and recognition by the immune system. RHuT-gD, a cell 128 
surface associated form, was assembled by fusing the N-terminal 1-390 aminoacids (aa.) region of rat 129 
HER-2 with 299 amino acids (residues 301-691) derived from the C-terminal region of human HER-2 130 
and gD106, a 33 peptide tag derived from bovine herpesvirus-1 glycoprotein D 35 (see Supplementary 131 
Fig. 1). RRT-gD, a secreted form lacking the transmembrane domain, was constructed by fusing the 132 
N-terminal 1-390  amino acids region of rat HER-2 with the gD106 tag peptide (Supplementary Fig. 133 
2). An additional secreted form, potentially capable of interacting with Fc receptors and designated 134 
RRT-Fc, was generated by substituting the HgD106 region of RHuT-gD with a stretch of 240 amino 135 
acids derived from the C-terminus of mouse IgG Fc (see Supplementary Fig. 3). RHuT-gD, RRT-gD 136 
and  RRT-Fc were all placed under the transcriptional control of the CMV promoter and the bovine 137 
growth hormone polyadenylation signal to obtain the CMV-RHuT-gD, CMV-RRT-gD and CMV-138 
RRT-Fc expression cassettes. The latter cassettes were excised from the plasmid backbone and sub-139 
cloned into the pINT2 shuttle vector containing two BoHV-4 TK flanking sequences 24, in order to 140 
generate the targeting vectors pTK-CMV-RHuT-gD-TK (pINT2-RHuT-gD), pTK-CMV-RRT-gD-TK 141 
(pINT2-RRT-gD) and pTK-CMV-RRT-Fc-TK (pINT2-RRT-Fc) (Fig. 1A, B and C). The resulting 142 
constructs were functionally validated in terms of protein expression by transient transfection into 143 
HEK 293T cells and immunoblotting with a monoclonal antibody directed against the gD106 tag 144 
peptide. All three chimeric proteins were well expressed in transfected cells (Fig. 1D, E and F) and, as 145 
expected, RRT-gD and RRT-Fc were found to be secreted (data not shown). 146 
 147 
Immunogenicity profiling of the different HER-2 constructs delivered to syngeneic mice by 148 
DNA vaccination 149 
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Although all three targeting vectors (pINT2-RHuT-gD, pINT2-RRT-gD and pINT2-RRT-Fc) led to 150 
high chimeric Her-2 protein levels in HEK 293T cells, we wished to evaluate their immunogenic 151 
properties more directly before converting them to the corresponding viral delivery vectors. To this 152 
end, three groups of BALB/c mice (6 animals/group) were immunized twice, at two-weeks intervals, 153 
with 50 µg of each plasmid and anti-rat Her-2 humoral and cellular immune responses were evaluated 154 
two weeks after the second vaccination. A targeting vector, pTK-CMV-A29gD-TK (pINT2-A29-gD), 155 
carrying an unrelated antigen from Monkeypoxvirus 36, was administered to a fourth group of mice and 156 
served as a negative control. Only mice vaccinated with pINT2-RHuT-gD, the plasmid coding for the 157 
membrane-bound form of the antigen, yielded a well-detectable anti-rat-Her-2 antibody response (Fig. 158 
2A). However, as revealed by parallel in vivo cytotoxicity assays using lysis of syngeneic splenocytes 159 
pulsed with the immune-dominant (H-2d) rat Her-2 peptide TYVPANASL as readout, all plasmids 160 
elicited a specific anti rat-HerR-2 cellular immune response (Fig. 2B). Similarly, all plasmids triggered 161 
IFN-γ-producing cells upon TYVPANASL peptide re-stimulation in ELISPOT assays (Fig. 2C).  162 
To determine immunogenicity in a mouse model more closely resembling the cancer situation (i.e., 163 
HER-2 overexpression), we next evaluated the ability of pINT2-RHuT-gD, pINT2-RRT-gD and 164 
pINT2-RRT-Fc to induce anti-rat Her-2 antibodies in BALB-neuT mice 37. These mice display a central 165 
tolerance with deletion of rat Her-2 TYVPANASL peptide-reactive CD8+ T cells 14, 15. Following 166 
vaccination (16-week-old BALB-neuT mice; n=7 per group), only animals receiving the pINT2-RHuT-167 
gD plasmid displayed a significant anti-rat Her-2 humoral immune response (see Supplementary Fig. 168 
4). As expected, given the expression of rat-Her-2 in the thymus of newborn BALB-neuT mice 21, these 169 
animals failed to mount any in vivo cytotoxic response against the TYVPANASL peptide and no IFN-γ 170 
was produced by splenocytes derived from vaccinated BALB-neuT mice upon TYVPANASL re-171 
stimulation (data not shown). 172 
Despite the unique ability of pINT2-RHuT-gD to elicit anti-rat Her2 antibodies in both mouse strains, 173 
all plasmids appeared to be capable to induce cellular immune responses in BALB/c mice. Therefore all 174 
three targeting vectors were carried on and used to construct the corresponding recombinant viruses. 175 
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 176 
Construction of recombinant BoHV-4 viruses containing different HER-2 expression cassettes 177 
The genome molecular clone of a safe BoHV-4 isolate (designated as BoHV-4-A) derived from the 178 
milk cell fraction of a clinically healthy cow 26 was used to construct the three recombinant HER2-179 
BoHV-4 vectors (BoHV-4-RHuT-gD, BoHV-4-RRT-gD and BoHV-4-RRT-Fc) plus a control viral 180 
vector (BoHV-4-A29-gD) delivering a completely unrelated antigen. To this end, pINT2-RHuT-gD,  181 
pINT2-RRT-gD, pINT2-RRT-Fc and the pINT2-A29-gD plasmid vectors were first linearized by a 182 
restriction enzyme digestion sparing the BoHV-4 TK flanking regions. Linearized plasmids were then 183 
electroporated into SW102 E. coli cells containing the artificial chromosome pBAC-BoHV-4-A-184 
KanaGalKΔTK  26, 38, 39 (Fig. 3A), in order to generate pBAC-BoHV-4-A-CMV-RHuT-gD-ΔTK, 185 
pBAC-BoHV-4-A-CMV-RRT-gD-ΔTK, pBAC-BoHV-4-A-CMV-RRT-Fc-ΔTK (Fig. 3B) and pBAC-186 
BoHV-4-A-CMV-A29-gD-ΔTK artificial chromosomes via heat-inducible homologous recombination 187 
40. The TK locus of the BoHV-4 genome is extremely stable even after repeated passages in vitro and in 188 
vivo, and it can thus be reliably employed to integrate foreign DNA sequences into the BoHV-4 genome 189 
without any transgene or viral replication efficiency loss due to recombination 24-30. 190 
Selected SW102 E. coli clones carrying pBAC-BoHV-4 recombinants were analyzed by HindIII 191 
restriction enzyme digestion and confirmed by DNA blotting with probes specific for the three 192 
chimeric ORFs (Fig. 3B). Stability of the pBAC-BoHV-4 recombinant clones in E. coli cells (i.e., the 193 
absence of restriction pattern alterations upon artificial chromosome propagation) was verified by 194 
restriction enzyme digestion after multiple (up to 20) serial passages (see Supplementary Fig. 5). 195 
To produce viable, replication-competent recombinant viral particles, pBAC-BoHV-4-A-CMV-RHuT-196 
gD-ΔTK, pBAC-BoHV-4-A-CMV-RRT-ΔTK, and pBAC-BoHV-4-A-CMV-RRT-Fc-ΔTK DNA 197 
constructs were electroporated into standard or cre recombinase-expressing BEK cells. The latter cells 198 
stably express the phage D1 cre recombinase 26 and allow for the site-specific removal of the floxed, 199 
GFP cassette-containing BAC sequence from the BAC-BoHV-4 genome. As a consequence of this 200 
removal and new cassette insertion, viral plaques generated on a BEKcre cell monolayer lost the 201 
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characteristic GFP fluorescence compared to parallel plaques seeded onto a standard BEK cell 202 
monolayer (Fig. 4A, D and G). Although viable BoHV-4-RHuT-gD, BoHV-4-RRT-gD and BoHV-4-203 
RRT-Fc virus particles were successfully reconstituted in BEK or BEKcre cells, as demonstrated by the 204 
cytopathic effect (CPE) observed in the cell monolayer, it was of interest to determine their replication 205 
properties with respect to the parental BoHV-4-A virus. As apparent in Fig. 4B, E and H, BoHV-4-206 
RHuT-gD, BoHV-4-RRT-gD and BoHV-4-RRT-Fc, all displayed a slower replication rate compared to 207 
the reference BoHV-4-A type. Furthermore, as revealed by immunoblotting analysis of infected cell 208 
extracts, they all expressed the corresponding HER-2 transgenes (Fig. 4C, F and I) and, as expected, 209 
BoHV-4-RHuT-gD targeted transgene expression to the cell membrane (see Supplementary Fig. 6). 210 
 211 
Higher immunogenicity of HER-2 antigens delivered as BoHV-4 recombinant viral particles 212 
compared to DNA immunization 213 
To test the immunogenicity of the different recombinant virus particles, four groups of BALB/c mice 214 
(7 animals/group) were vaccinated twice intraperitoneally (i.p.), at two weeks intervals, with BoHV-4-215 
RHuT-gD, BoHV-4-RRT-gD and BoHV-4-RRT-Fc, plus the unrelated BoHV-4-A29-gD control. Two 216 
weeks after the second immunization, sera were collected and tested for the presence of anti-rat-Her-2 217 
antibodies. No specific anti-rat-Her-2 humoral immune response was detected in mice vaccinated with 218 
either BoHV-4-RRT-gD or BoHV-4-RRT-Fc. In contrast, BoHV-4-RHuT-gD viral particles elicited a 219 
sustained anti-rat-Her-2 antibody response (Fig. 5A), significantly higher (~2.5-fold) than the one 220 
previously detected in BALB/c mice immunized with the pINT2-RHuT-gD plasmid (p=0.02) (Fig. 221 
2A). Also, while BoHV-4-A29-gD viral particles did not induce any appreciable cytotoxic response 222 
against TYVPANASL-pulsed syngeneic splenocytes, all HER-2 containing recombinant BoHV-4 viral 223 
particles induced a strong cytotoxicity (Fig. 5B), significantly higher (~3-fold) than that induced by the 224 
corresponding pINT2 plasmids delivered through DNA vaccination (p=0.009 for BoHV-4-RHuT-gD 225 
vs. pINT2-RHuT-gD; p=0.03 for BoHV-4-RRT-gD vs. pINT2-RRT-gD; p<0.0001 for BoHV-4-RRT-226 
Fc vs. pINT2-RRT-Fc). Similarly, IFN-γ–producing cells were induced at high frequency by 227 
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TYVPANASL peptide restimulation of BoHV-4-HER-2- vaccinated mice (Fig. 5C), with no 228 
statistically significant difference between the three experimental groups. 229 
 230 
BoHV-4-RHuT-gD affords a significant protection against rat-HER-2-driven mammary 231 
carcinogenesis in BALB-neuT mice. 232 
In HER-2-tolerant BALB-neuT mice, similarly to what we observed after vaccination with pINT2 233 
plasmid DNA  (Supplementary Fig. 4), only BoHV-4-RHuT-gD (i.e., BoHV-4-A containing the 234 
RHuT-gD expression cassette) effectively induced anti-rat-Her-2 antibodies, at levels considerably 235 
higher (~3 folds) than those elicited by pINT2 (Fig. 6A). The superior immunogenicity of BoVH-4-236 
RHuT-gD is also supported by the earlier appearance of anti-rat Her-2 antibodies, which were already 237 
well detectable after the first vaccination and increased thereafter, reaching titers significantly higher 238 
than those elicited by pINT2-RHuT-gD (p<0.0001). Most importantly, the presence of anti-rat-Her-2 239 
antibodies in sera from BALB-neuT mice vaccinated with BoHV-4-RHuT-gD correlated with a 240 
significant delay of mammary tumor appearance. In fact, 50% of BoHV-4-RHuT-gD-vaccinated 241 
BALB-neuT mice were completely tumor-free at week 30, when 100% of BoHV-4-RRT-gD- and 242 
BoHV-4-RRT-Fc-vaccinated animals already displayed at least one palpable tumor (Fig. 6B). 243 
  244 
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DISCUSSION 245 
The aim of this study was to investigate the potential of BoHV-4 as a safe, potent and large-capacity 246 
vaccine vector able to deliver HER-2-derived engineered antigens and to protect HER-2 transgenic, 247 
BALB-neuT mice from autochthonous mammary cancer. BALB-neuT mice were used as a model 248 
system because they share a number of features with human breast cancer. In fact, following multi-step 249 
progression 15, each BALB-neuT mammary gland spontaneously develops an independent rat-Her-250 
2+tumor 12, 41, which becomes invasive and metastatizes to the bone marrow first and subsequently to 251 
the lungs 42. Moreover, similarly to patients with rat Her-2+ carcinomas, BALB-neuT mice lack high-252 
affinity, Her-2 peptide-recognizing cytotoxic T lymphocytes  14, with an expansion of T regulatory  15 253 
and myeloid immature suppressor cells 43 during carcinogenesis progression. For all these reasons, 254 
BALB-neuT mice represent an excellent model system to set up and test novel therapeutic and 255 
immune-prophylactic approaches to control breast cancer 37. 256 
In this system, BoHV-4-delivered, membrane-bound rat-human Her-2 proved to be superior to the 257 
same antigen delivered through DNA vaccination with regard to tolerance breaking, humoral immune 258 
response induction and prevention of mammary tumor formation. 259 
Initially, CMV-RHuT-gD, CMV-RRT-gD and CMV-RRT-Fc expression cassettes were successfully 260 
tested in terms of immune response by DNA vaccination. While all plasmids were able to induce a 261 
significant anti-rat Her-2 cellular immune response, only mice vaccinated with pINT-2-RHuT-gD 262 
induced a significant production of anti-rat Her-2 antibodies. As expected and already seen in other rat-263 
HER-2 transgenic (CB6F1-neuT) mice vaccinated with a DNA plasmid coding for RHuT, the antibody 264 
titer measured in BALB-neuT mice was significantly lower than that of BALB/c mice, being the former 265 
deeply tolerant to rat-Her-2 protein 21. We then constructed the three corresponding BoHV-4 vectors 266 
and evaluated their replication capacity by comparison with the parental BoHV-4-A strain. HER-2-267 
containing recombinant viruses displayed a slower replication, likely attributable to a toxic effect caused 268 
by transgene overexpression. Despite their lower replication rate, however, all recombinant viruses 269 
abundantly expressed HER-2-derived transgenes in infected cells and triggered sustained T cell immune 270 
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responses in BALB/c mice. In contrast, and in keeping with the notion that sub-cellular localization of 271 
viral vectored transgenes critically affects antigen presentation to, and processing by, the immune 272 
system, membrane-targeted BoHV-4-RHuT-gD, but neither of the two secreted BoHV-4-HER-2 273 
derivatives, was found to be capable of inducing a strong humoral anti-HER-2 response in BALB/c 274 
and BALB-neuT mice. In both mouse strains, the intensity of this response was significantly higher 275 
than that observed in mice vaccinated with the RHuT-encoding pINT-2 plasmid and an earlier anti-rat 276 
Her-2 antibody response, already detectable after the first vaccination, was observed in BALB-neuT 277 
mice. This sustained antibody production likely explains the striking delay in mammary cancer 278 
appearance brought about by BoHV-4-RHuT-gD vaccination. In fact, anti-rat Her-2 antibodies have 279 
previously been shown to cause a marked downregulation and cytoplasmic confinement of rat Her-2 280 
both in vitro  13, 41 and in vivo 12, 21, with a concomitant impairment of Her-2 mediated PI3K/Akt signaling 281 
44. In addition, anti-Her-2 antibodies may activate complement-mediated lysis and antibody-dependent 282 
cytotoxicity 12, 21. 283 
Various anti-Her-2 vaccine formulations have been tested in recent years, both in preclinical cancer 284 
models and in the clinic. These include allogenic Her-2+ tumor cells 45-48, Her-2 peptide-presenting 285 
autologous dendritic cells 48, 49, Her-2 protein/peptide immunogens 50, 51, Her-2-based DNA vaccines 12, 286 
21, 23, 41, 52, virus-like particles carrying Her-2  53, 54 and even a chimeric recombinant Her-2 antigen 287 
expressed by an attenuated strain of Listeria monicytogenes 55. Viral delivery vectors, instead, have received 288 
much less attention, recombinant vaccinia  56, 57 and adenovirus based vectors are the only viral vectors 289 
tested, with quite encouraging results, so far 58, 59. This likely reflects potential concerns with safety and 290 
anti-vector immunity. Since risk associated with virus-mediated delivery represents a major issue in viral 291 
vector development, attenuation is usually regarded as a highly desirable feature and many efforts are 292 
directed toward the development of highly attenuated viral strains with decreased virulence. In this 293 
study, we took advantage of the natural non-pathogenicity of BoHV-4, which was previously proved in 294 
both standard and genetically modified mouse strains 28, 33. Further to this point, we also previously 295 
inoculated high BoHV-4 doses intracerebrally with no apparent negative side-effect, and found that the 296 
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virus effectively transduced brain cells in the area of inoculation, leading to high-level expression of the 297 
GFP transgene 60. Therefore, BoHV-4 naturally behaves as a replication-incompetent viral vector that 298 
does not require further attenuation. One other major advantages of BoHV-4 is its natural inability to 299 
induce serum neutralizing antibody responses. This alleviates most concerns regarding the occurrence 300 
of pre-existing, host anti-vector antibodies (as it is the case for adenovirus-based vectors) and allows for 301 
multiple immunizations, if required. 302 
In conclusion, our study highlights the favorable properties and potential advantages of BoHV-4 as a 303 
highly effective viral vector for cellular Her-2 delivery in order to achieve mammary cancer prophylaxis 304 
through a potential one-shot active immunization. Given the previous demonstration of the oncolytic 305 
properties of BoHV-4 29, future work will address the feasibility (and efficacy) of combined 306 
prophylactic and therapeutic approaches based on the use of this particular viral vector. 307 
 308 
  309 
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Materials and Methods 310 
 311 
Cell lines 312 
Bovine embryo kidney [(BEK) from Dr. M. Ferrari, Istituto Zooprofilattico Sperimentale, Brescia, 313 
Italy; (BS CL-94)], BEK expressing cre recombinase (BEK cre) 26 , Human Embryo Kidney 293T 314 
[(HEK 293T) ATCC: CRL-11268] , Mus musculus mammary gland [(NMuMG) ATCC: CRL-1636] and  315 
NIH3T3 murine fibroblasts expressing rat-Her-2 protein (3T3/NKB cells) 61 cell lines were cultured in 316 
complete growth medium Eagle's minimal essential medium (EMEM, Lonza) containing 10% fetal 317 
bovine serum (FBS), 2 mM of L-glutamine (SIGMA), 100 IU/mL of penicillin (SIGMA), 100 μg/mL 318 
of streptomycin (SIGMA) and 2.5 μg/mL of Amphotericin B (SIGMA) and incubated at 37°C, 5% 319 
CO2. 320 
 321 
PCR 322 
The 2067 pb rat-human transmembrane protein (RHuT) and the 1250 pb rat extracellular  domain 323 
(ECD) of rat Her-2 protein (RRT) were amplified from pVAX RHut plasmid 62 with NheI-RHut sense 324 
(5’- CCCGCTAGCCCACCATGATCATCATGGAGCTGGCGGCC-3’) and SalI-RHut antisense (5’-325 
CCCCGAGTCGACCTTCCGGATCTTCTGCTGCCGTCG-3’) and with NheI-RRT sense (5’- 326 
CCCGCTAGCCCACCATGATCATCATGGAGCTG-3’) and SalI-RRT antisense (5’-327 
CCCCGAGTCGACTGTGATCTCCTCCAGGGTTTCGAACACTTGGAG3’) primer pairs, 328 
respectively.  329 
The PCR amplification reactions were carried out in a final volume of 50 μl, containing 10 mM Tris–330 
hydrochloride pH 8.3, 0.2mM deoxynucleotide triphosphates, 3 mM MgCl2, 50 mM KCl and 0.25 μM 331 
of each primer. One hundred nanograms of DNA was amplified over 35 cycles, each cycle consisting 332 
of denaturation at 94°C for 1 min, primer annealing at 55°C for 1 min and chain elongation with 1U of 333 
Pfu DNA polymerase (Fermentas) at 72°C for 150 sec, in the case of RHut, and at 72°C for 90 sec, in 334 
the case of RRT.  The so generated 2067 bp and 1250 pb amplicons were then checked in 1% agarose 335 
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gel and visualized after ethidium bromide staining in 1× TAE buffer (40 mM Tris-acetate, 1 mM 336 
EDTA).  337 
 338 
Constructs generation 339 
The NheI-RHut-SalI amplified fragment (2067 pb) was firstly sub-cloned inside the previously 340 
NheI/SalI digested pIgkE2gD106, an eukaryotic expression vector containing a gD106 epitope of 341 
Bovine herpesvirus 1 glycoprotein D, successfully used as a tag during the cloning 35. The obtained 342 
pIgkRHuTgD106 was subsequently digested with NheI/BamHI to  insert the 2169 fragment RHutgD106 343 
into pEGFP-C1 vector (Addgene), digested with the same enzymes, to remove EGFP gene and to 344 
generate pCMVRHuTgD106.  Finally, the 2421 pb Nhe/MluI-blunt ended fragment, containing 345 
RHuTgD106 with Simian Virus 40 poly A, was excised and inserted inside pINT2EGFPTK shuttle 346 
vector 24, cut with NheI/SmaI restriction enzymes, to obtain pINT2-RHuT-gD.  347 
The amplified NheI-RRT-SalI (1250 pb) fragment was sub-cloned into NheI/SalI previously digested 348 
pIgkE2gD106 35 and pIgkE2Fc, an eukaryotic expression vector expressing the crystallizable fragment 349 
(Fc) of mouse Immunoglobulin, used as a tag and soluble secreted frgment. RRT-gD106 (1352 pb) and 350 
RRTFc (1992 pb) were excised with the double digestion NheI/BamHI and inserted into 351 
NheI/BamHI digested pEGFP-C1 (Addgene), to remove EGFP gene and generate pCMV-RRT-352 
gD106 and pCMV-RRT-Fc. NheI/MluI-blunt ended fragments containing RRT-gD106 (1604 pb) or 353 
RRT-Fc (2244), containing the Simian Virus 40 poly A, were excised and inserted inside 354 
pINT2EGFPTK shuttle vector 24, cut with NheI/SmaI restriction enzymes, to obtain pINT2-RRT-gD 355 
and pINT2-RRT-Fc. 356 
 357 
Transient Transfection  358 
Confluent HEK293T cells were seeded into 6 well plates (3x105 cells/well) and incubated at 37 °C with 359 
5% CO2; when the cells were sub-confluent the culture medium was removed and the cells were 360 
transfected with pINT2-RHuT-gD, pINT2-RRT-gD and pINT2-RRT-Fc, using Polyethylenimine (Pei) 361 
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transfection reagent (Polysciences, Inc.). Briefly, 3 μg of DNA were mixed with 7,5 μg PEI (1mg/mL) 362 
( ratio 1:2.5 DNA- Pei) in 200 μL of Dulbecco’s modified essential medium (DMEM) at high glucose 363 
percentage (Euroclone) without serum. After 15 min at RT, 800 μL of medium without serum were 364 
added and the transfection solution was transferred to the cells and left on the cells for 6 h at 37oC with 365 
5% CO2 in air, in a humidified incubator. The transfection mixture was then replaced with fresh 366 
medium (EMEM, with 10% FBS, 50 IU/mL of penicillin, 100 μg/mL of streptomycin and 2.5 μg/mL 367 
of Amphotericin B) and incubated for 24 h at 37oC with 5% CO2. 368 
 369 
Viruses  370 
BoHV-4-RHuT-gD, BoHV-4-RRT-gD, BoHV-4-RRT-Fc and BoHV-4-A were propagated by 371 
infecting confluent monolayers of BEK cells at a multiplicity of infection (MOI) of 0.5 50% tissue 372 
culture infectious doses (TCID50) per cell and maintained in medium with only 2% FBS for 2 h. The 373 
medium was then removed and replaced with fresh EMEM containing 10% FBS. When the cytopathic 374 
effect (CPE) interested the majority of the cell monolayer (∼72 h post infection), the virus was prepared 375 
by freezing and thawing cells three times and pelleting the virions through a 30% sucrose cushion, as 376 
described previously 60. Virus pellets were then resuspended in cold EMEM without FBS. TCID50 were 377 
determined with BEK cells by limiting dilution. 378 
 379 
Western Immunoblotting 380 
Protein cell extracts were obtained from a 6-well confluent plate of HEK293T transfected with pINT2-381 
RHuT-gD, pINT2-RRT-gD and pINT2-RRT-Fc and from 25-cm2 confluent flasks of BEK infected 382 
with BoHV-4-RHuT-gD, BoHV-4-RRT-gD, BoHV-4-RRT-Fc by adding 100 μL of cell extraction 383 
buffer (50 mM Tris–HCl, 150 mM NaCl, and 1% NP-40; pH 8). A 10% SDS–PAGE gel 384 
electrophoresis was used to analyze cell extracts containing 50 μg of total protein, after protein transfer 385 
in nylon membranes by electroblotting, the membranes were incubated with primary bovine anti 386 
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BoHV-1 glycoprotein D monoclonal antibody (clone 1B8-F11; VRMD, Inc., Pullman, WA), diluited 387 
1:15.000, and then with a secondary antibody probed with horseradish peroxidase-labelled anti-mouse 388 
immunoglobulin (A 9044; Sigma), diluited 1:10.000, to be visualized by enhanced chemiluminescence 389 
(ECL Kit; Pierce). pINT2-RRT-Fc and BoHV-4-RRT-Fc protein extracts were directly incubated with 390 
the secondary antibody probed with horseradish peroxidase-labelled anti-mouse immunoglobulin (A 391 
9044; Sigma), recognizing the Fc tag. 392 
 393 
BAC Recombineering and selection 394 
Recombineering was performed as previously described 40 with some modifications. Five hundred 395 
microliters of a 32°C overnight culture of SW102 containing BAC-BoHV-4-A-Kana-GalKΔTK, were 396 
diluted in 25 ml Luria–Bertani (LB) medium with or without chloramphenicol (SIGMA) selection (12.5 397 
mg/ml) in a 50 mL baffled conical flask and grown at 32°C in a shaking water bath to an OD600 of 0.6. 398 
Then, 10 mL were transferred to another baffled 50 mL conical flask and heat-shocked at 42°C for 399 
exactly 15 min in a shaking water bath. The remaining culture was left at 32°C as the un-induced 400 
control. After 15 min the two samples, induced and un-induced, were briefly cooled in ice/water bath 401 
slurry and then transferred to two 15 mL Falcon tubes and pelleted using 5000 r.p.m. (eppendorf 402 
centrifuge) at 0°C for 5 min. The supernatant was poured off and the pellet was resuspended in 1mL 403 
ice-cold ddH2O by gently swirling the tubes in ice/water bath slurry. Subsequently, 9 mL ice-cold 404 
ddH2O were added and the samples pelleted again. This step was repeated once more, the supernatant 405 
was removed and the pellet (50 μL each) was kept on ice until electroporated with gel-purified PvuI 406 
(Fermentas) linearized pINT2-RHuT-gD, pINT2-RRT-gD and pINT2-RRT-Fc. An aliquot of 25 μl was 407 
used for each electroporation in a 0.1 cm cuvette at 25 μF, 2.5 kV and 201Ω. After electroporation, for 408 
the counter selection step, the bacteria were recovered in 10 mL LB in a 50 mL baffled conical flask 409 
and incubated for 4.5 h in a 32°C shaking water bath. Bacteria serial dilutions were plated on M63 410 
minimal medium plates containing 15g/L agar, 0.2% glycerol, 1mg/L D-biotin, 45mg/L L-leucine, 411 
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0.2% 2- deoxy-galactose and 12.5 mg/mL chloramphenicol. All the complements for M63 medium 412 
were purchased from SIGMA. 413 
Plates were incubated 3–5 days at 32°C; then several selected colonies were picked up, streaked on 414 
McConkey agar indicator plates (DIFCO, BD Biosciences) containing 12.5 mg/mL of chloramphenicol 415 
and incubated at 32°C for 3 days until white colonies appeared. White colonies were grown in duplicate 416 
for 5–8 h in1mL of LB containing 50 mg/mL of kanamycin (SIGMA) or LB containing 12.5 mg/mL 417 
of chloramphenicol. Only those colonies that were kanamycin negative and chloramphenicol positive 418 
were kept and grown overnight in 5 mL of LB containing 12.5 mg/mL of chloramphenicol. BAC DNA 419 
was purified and analyzed through HindIII restriction enzyme digestion. DNA was separated by 420 
electrophoresis overnight in a 1% agarose gel, stained with ethidium bromide, and visualized to UV 421 
light.  422 
Original detailed protocols for recombineering can also be found at the recombineering website 423 
(http://recombineering.ncifcrf.gov). 424 
 425 
Non isotopic Southern blotting  426 
DNA from 1% agarose gel was capillary transferred to a positively charged nylon membrane (Roche), 427 
and cross-linked by UV irradiation by standard procedures 26.  428 
The membrane was pre-hybridized in 50 mL of hybridization solution (7% SDS, 0.5 M phosphate, pH 429 
7.2) for 1 h at 65°C in a rotating hybridization oven (Techna instruments). The 1250 bp amplicon for 430 
RRT digoxigenin-labeled probe was generated by PCR with the primers NheI-RRT sense and SalI-RRT 431 
antisense, as previously described 27. PCR amplification was carried out in a final volume of 50 μL of 10 432 
mM Tris–HCl, pH 8.3, containing 0.2 mM deoxynucleotide triphosphates, 0.02 mM alkaline labile 433 
digoxigenin-dUTP (Roche), 3 mM MgCl2, 50 mM KCl, and 0.25 μM of each primer over 35 cycles, 434 
each cycle consisting of denaturation at 94°C for 1 min, primer annealing at 55°C for 1 min, and chain 435 
elongation with 1 U of Taq polymerase (Thermoscientific) at 72°C for 90 sec. A parallel reaction 436 
omitting digoxigenin dUTP was performed, because digoxigenin incorporation into the amplicon can 437 
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be checked through the size shift of the amplicon by gel electrophoresis. Five microliters of the probe 438 
were added to 500 μL of dH2O into a screw-cap tube, denatured in boiling water for 5 min, and cooled 439 
down on ice for another 2 min. Denatured probe was added to 50 mL of pre-heated 65°C hybridization 440 
solution (7% SDS, 0.5 M phosphate, pH 7.2 and 1 mM EDTA) to the pre-hybridized membrane and 441 
hybridized overnight at 65°C in a rotating hybridization oven (Techna Instruments). Following 442 
hybridization, the membrane was washed twice for 30 min with 100 mL of washing solution I (0.5× 443 
SSC [1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate] and 0.1% SDS) and twice for 30 min with 444 
100 mL of washing solution II (40 mM phosphate, pH 7.2, 0.05% SDS) at 65 °C. On a freshly washed 445 
dish, the membrane was incubated for 30 min at room temperature in 100 mL of blocking solution 446 
(100 mM maleic acid, pH 7.5, 150 mM NaCl, 1% blocking reagent [Roche]). Anti-digoxigenin Fab 447 
fragment (150 U/200 μL [Roche]), diluted 1:15.000 in 50 mL of blocking solution, was applied to the 448 
membrane for 30 min under gentle shaking at room temperature and washed twice for 15 min with 100 449 
mL of washing solution (100 mM maleic acid, pH 7.5, 150 mM NaCl, 0.3% Tween 20). Detection was 450 
performed following equilibration of the membrane in detection buffer (100 mM Tris–HCl, pH 9.5, 1 451 
mM EDTA) for 2 min at room temperature. Chemiluminescent substrate (CSPD, Roche) was added by 452 
scattering the drops over the surface of the membrane after placement of the membrane between two 453 
plastic sheets, and any bubbles present under the sheet were eliminated with a damp lab tissue to create 454 
a liquid seal around the membrane. Signal detection was obtained, exposing the membrane to X-ray 455 
film. The exposure time was adjusted with the intensity of the signal. 456 
 457 
Cell culture electroporation and recombinant virus reconstitution 458 
BEK or BEKcre cells were maintained as a monolayer with complete EMEM growth medium with 10% 459 
FBS, 2 mM L-glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin. 460 
When cells were sub-confluent (70–90%) they were split to a fresh culture vessel (i.e., every 3–5 days) 461 
and were incubated at 37°C in a humidified atmosphere of 95% air–5% CO2.  462 
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BAC DNA (5 μg) was electroporated in 600 μL DMEM without serum (Equibio apparatus, 270 V, 960 463 
mF, 4-mm gap cuvettes) into BEK and/or BEKcre cells from a confluent 25-cm2 flask. Electroporated 464 
cells were returned to the flask, after 24 h the medium was replaced with fresh medium, and cells were 465 
split 1:2 when they reached confluence at 2 days post-electroporation. Cells were left to grow until the 466 
appearance of CPE. Recombinant viruses were propagated by infecting confluent monolayers of BEK 467 
cells at a M.O.I. of 0.5 TCID50 per cell and maintaining them in MEM with 10% FBS for 2 h. 468 
 469 
Viral growth curves  470 
BEK cells were infected with BoHV-4-A, BoHV-4-RHuT-gD, BoHV-4-RRT-gD, BoHV-4-RRT-Fc at 471 
a M.O.I. of 0,1 TCID50/cell and incubated at 37°C for 4 h. Infected cells were washed with serum-free 472 
EMEM and then overlaid with EMEM containing 10% FBS, 2 mM Lglutamine, 100 IU/mL penicillin, 473 
100 µg/mL streptomycin and 2.5 µg/mL Amphotericin B. The supernatants of infected cultures were 474 
harvested after 24, 48, 72 and 96 h, and the amount of infectious virus was determined by limiting 475 
dilution on BEK cells. 476 
 477 
Mice 478 
BALB/c (Charles River) and BALB-neuT (Ariano Irpino, Italy) 63 mice were bred under specific 479 
pathogen-free conditions (Allentown Caging Equipment, Allentown, NJ, USA) at the Molecular 480 
Biotechnology Center (Torino, Italy) and treated according to the European Guidelines and policies, as 481 
approved by the University of Torino Ethical Committee. To assess mammary tumor incidence BALB-482 
neuT females were inspected weekly by palpation, and progressively growing masses with a mean 483 
diameter of >1 mm were regarded as tumors. Each tumor mass was measured with a calliper in the two 484 
perpendicular diameters. Growth was monitored until all 10 mammary glands displayed a tumor or 485 
until a tumor exceeded a mean diameter of 10 mm, at which time mice were sacrificed for humane 486 
reasons. 487 
 488 
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Mice immunization 489 
Recombinant pINT2 plasmids were purified by large scale preparation using the EndoFree Plasmid 490 
Giga kits (Qiagen, Inc., CA, USA). 10 week-old BALB/c and BALB-neuT mice were anesthetized by 491 
intramuscular injection (i.m.) of 40 μL of a solution containing 5,7 μL of Zoletil 100 (Vibrac, Milano, 492 
Italia), 3,5 μL of Rompum (Bayer, Milano, Italia) and 37,5 μL of Phosphate Buffer Saline (PBS) 493 
(GIBCO, Grand Island, NY, USA). Anesthetized mice were injected in the quadriceps muscle with 50 494 
μg of plasmid DNA diluted in 20 μL of saline solution. Immediately after injection, two 25-ms trans-495 
cutaneous electric low voltage pulses with amplitude of 150 V and a 300 ms interval were administered 496 
at the injection site via a multiple needle electrode connected to the Cliniporator™ (IGEA s.r.l., Carpi, 497 
Italy). The DNA vaccination course consisted of two i.m. injections of plasmid followed by 498 
electroporation repeated with an interval of 14 days. 499 
106 TCID50 recombinant BoHV-4 viral particles were diluted in 200 μL of Dubecco’s Modified Eagle 500 
Medium (DMEM; Gibco, Rockville, MD) and injected intraperitoneal (i.p.) twice at two weeks interval 501 
in groups of 10 week-old BALB/c or BALB-neuT females. 502 
 503 
Anti-rat-Her-2 antibody response 504 
Two weeks after the second immunization, mice were bled and their sera were tested by flow cytometry 505 
for their ability to bind 3T3/NKB cells 61. Briefly, sera diluted 1:100 in PBS were incubated for 30 min 506 
at 4°C with 2 x 105 3T3/NKB cells pre-treated with Fc receptor blocker (CD16/CD32; Pharmingen, 507 
St. Diego, CA) for 5 min at 4°C. The Ab4 mAb (Calbiochem, San Diego, CA), was used as positive 508 
control for rat Her-2 positivity. After washes with PBS containing 2% bovine serum albumin (BSA, 509 
Sigma-Aldrich, Milano, Italy) and 0.1% NaN3 (Sigma-Aldrich) (wash solution) cells were incubated 510 
with 1:50 dilution of a FITC-conjugate anti-mouse immunoglobulin G (IgG) Fc antibody 511 
(DakoCytomation, Milano, Italy) for 30 min at 4°C. Washed cells were then acquired and analyzed on 512 
the CyAn ADP using Summit 4.3 software (DakoCytomation, Heverlee, Belgium). The results were 513 
expressed as Mean Fluorescence Intensity (MFI). 514 
23 
 
 515 
Anti-rat-Her-2 cellular immune response 516 
To prepare target cells for in vivo cytotoxicity detection, spleens from BALB/c and BALB-neuT mice 517 
were mechanically dissociated and the erythrocytes were removed from the cells suspension by osmotic 518 
lysis. Cells were then washed and labeled with two different CFSE (carboxyfluorescein-diacetate-519 
succinimidyl ester) (Molecular Probes Invitrogen, Carlsbad, CA) concentration (5 and 0.5 μM). Cells 520 
labelled with 5 μM CFSE (CFSEhigh cells) were also pulsed with the rat-Her-2H2d dominant 521 
TYVPANASL peptide (INBIOS Srl) at a concentration of 15 μg/mL for 1 h at 37°C; those labelled 522 
with 0.5 μM CFSE (CFSElow cells) were left unpulsed. 10 x 106 CFSEhigh cells plus 10 x 106 CFSElow cells 523 
were injected in the tail vein of vaccinated mice. Forty eight h after spleen cells injection, mice were 524 
sacrificed and the presence of CFSEhigh and CFSElow in the spleen was measured by using a CyAn ADP 525 
Flow Cytometer (DakoCytomation). The percentage of the low peaks was normalized on control 526 
untreated low peaks and consequently the specific cytolytic activity was calculated as percentage of lysis 527 
as following described: 100 - {[(CFSElow untreated cells/ CFSElow experimental cells) x CFSEhigh 528 
experimental cells] x 100}/ CFSEhigh untreated cells. 529 
To measure the number of rat-Her-2specific IFN-γ releasing T lymphocytes a mouse IFN-γ ELISPOT 530 
assay kit purchased from BD Biosciences (San Jose, CA, USA) was used. Briefly, two weeks after the 531 
vaccination course, 0.5 x 106 spleen cells were added to the wells of 96-well HTS IP plates (Millipore, 532 
Billerica, MA) pre-coated with 5 μg/mL of rat anti-mouse IFN-γ (clone R4-6A2, BD Biosciences, San 533 
Jose, CA, USA). Spleen cells were stimulated with 15 μg/mL of TYVPANASL peptide (INBIOS Srl, 534 
Napoli, Italy) for 24 h at 37°C in a humidified 5% CO2 atmosphere. Concanavalin A (Sigma-Aldrich) at 535 
the concentration of 2 µg/mL and RPMI-1640 medium (Sigma-Aldrich) alone were used as positive 536 
and negative control, respectively. IFN-γ spots were scanned and counted using an ImmunoSpot Image 537 
Analyzer software (Aelvis, Germany). Results were plotted as median of spot values among triplicates. 538 
 539 
Immunofluorescence assay 540 
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For rat Her-2 detection, 4 × 105 Nmug cells were plated on glass coverslips and left to adhere overnight 541 
at 37 °C in a 5% CO2 incubator. The next day, cells were infected for 24 hours) with 0,5 TCID50/cell 542 
of BoHV-4-RHuT-gD or with the same TCID50/cell of BoHV-4-RHuT-gD inactivated at 70°C for 30 543 
minutes. After infection, cells were fixed with 4% formalin (Sigma-Aldrich) solution in PBS for 5 544 
minutes at room temperature, washed twice with PBS and blocked with 10% bovine serum albumin 545 
(BSA, Sigma-Aldrich) in PBS for 40 minutes at room temperature. Her-2 was detected incubating 546 
coverslips with an anti rat/Her-2 monoclonal antibody (1:20, clone number, Calbiochem, San Diego, 547 
CA) for 1 hour at room temperature in PBS containing 1% BSA. Cells were rinsed twice with PBS and 548 
then incubated with AlexaFluor488 goat anti-mouse (1:1000, clone A11017, Invitrogen) in PBS 549 
containing 1% BSA. Cells were rinsed three times with PBS and nuclei were counterstained with DAPI 550 
(Invitrogen). Coverslips were air dried and mounted with Fluoromount mounting medium (Sigma-551 
Aldrich) and visualized with Apotome fluorescence microscope (Leica,). Photographs were taken using 552 
a digital CCD camera and images were processed using the AxioVision software (Zeiss, V. 4.4). 553 
 554 
FACS analysis 555 
For rat Her-2 detection, 4 × 105 Nmug cells were plated and left to adhere overnight at 37 °C in a 5% 556 
CO2 incubator. The next day, cells were infected for 24 hours with 0,5 TCID50/cell of BoHV-4-557 
RHuT-gD or with the same TCID50/cell of BoHV-4-RHuT-gD inactivated at 70°C for 30 minutes. 558 
After infection, cells were detached with tripsin 1X (Invitrogen o Sigma), incubated with Fc receptor 559 
blocker (CD16/CD32; Pharmingen, St. Diego, CA) for 5 min at 4°C to block aspecific site. Her-2 was 560 
detected incubating cells with an anti rat/Her-2 monoclonal antibody (1:25, clone number, Calbiochem, 561 
San Diego, CA) for 30 min at 4°C. Then cells were washed with PBS containing 2% bovine serum 562 
albumin (BSA, Sigma-Aldrich, Milano, Italy) and 0.1% NaN3 (Sigma-Aldrich) (wash solution) and 563 
incubated with 1:50 dilution of a FITC-conjugate anti-mouse immunoglobulin G (IgG) Fc antibody 564 
(DakoCytomation, Milano, Italy) for 30 min at 4°C. Washed cells were then acquired and analyzed on 565 
the CyAn ADP using Summit 4.3 software (DakoCytomation, Heverlee, Belgium). 566 
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 567 
 568 
Statistical analysis 569 
Statistical differences were evaluated using GraphPad software 5.0 (GraphPad Inc.). The Mantel-Cox 570 
log-rank test was used to evaluate the differences in the tumor incidence between different 571 
experimental groups. The two-tailed unpaired Student’s t test was used to evaluate differences in the 572 
antibody titer, % of lysis and number of IFN-γ secreting T cells between different experimental groups. 573 
  574 
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FIGURE LEGENDS 763 
Figure 1. Design and expression of Her-2 chimeric proteins. Diagrams (not to scale) of (A) pTK-764 
CMV-RHuT-gD-TK (pINT2-RHuT-gD), (B) pTK-CMV-RRT-gD-TK (pINT2-RRT-gD) and (C) 765 
pTK-CMV-RRT-Fc-TK (pINT2-RRT-Fc) targeting vectors with expression cassettes under the control 766 
of the CMV promoter (pCMV, blue) and the bovine growth hormone polyadenylation signal (PA, 767 
orange). RHuT-gD (A) and RRT-gD (B) ORFs are tagged with the gD106 peptide (red), while the RRT-768 
Fc ORF (C) was fused to a mouse IgG Fc encoding fragment (grey). All expression cassettes are flanked 769 
by BoHV-4 TK homologous sequences (white). The results of immunoblotting analyses conducted with 770 
an anti-gD106 antibody on HEK 293Tcells transfected with pINT2-RHuT-gD, pINT2-RRT-gD and 771 
pINT2-RRT-Fc are shown in panels D-F, respectively. Individual lanes were loaded with different 772 
amounts of total protein cell extract (5, 10 and 20 μg); cells transfected with pEGFP-1 served as 773 
negative controls (Mock). 774 
 775 
Figure 2. Anti-rat-Her-2 immune responses induced by DNA vaccination with the different 776 
pINT2 expression plasmids. (A) Sera from BALB/c mice collected two weeks after the first (grey dots; 777 
n=6) and the second (black dots; n=6) vaccination were analyzed (at a dilution of 1:100) for the presence 778 
of specific anti-rat-Her-2 antibodies by flow cytometry. Results are expressed as mean fluorescence 779 
intensity (MFI) values for each serum. Horizontal lines represent median values (**: p=0.003, Student’s 780 
t test). (B) In vivo cytotoxic responses against the H2d dominant, rat Her-2 TYVPANASL peptide 781 
measured two weeks after the second vaccination in mice (n=3) immunized with the indicated pINT2 782 
plasmids; data are mean values ± SEM. (*: p=0.02; **: p=0.005; ***: p<0.0001; Student’s t-test). (C) T-783 
cell responses against the H2d dominant, rat Her-2 TYVPANASL peptide measured in vitro, two weeks 784 
after the second vaccination, in mice (n=3) immunized with the indicated pINT2 plasmids, using an 785 
IFN-γ-based ELISPOT assay. Data, expressed as SFU/1x106 SPC, are presented as mean ± SEM 786 
values (**: p=0.001, ***: p=0.0008; Student’s t-test). 787 
 788 
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Figure 3. Recombinant BoHV-4 constructs. (A) Diagram (not to scale) illustrating the re-targeting 789 
event (i.e., replacement of the Kana/GalK cassette with the CMV-RHuT-gD, CMV-RRT-gD and 790 
CMV-RRT-Fc expression cassettes) generated by heat-inducible homologous recombination in SW102 791 
E. coli cells containing pBAC-BoHV-4-A-TK-KanaGalK-TK. (B) Two representative, 2-deoxy-792 
galactose resistant colonies for each recombinant pBAC-BoHV-4 genome, tested by HindIII restriction 793 
enzyme analysis and DNA blotting performed with a probe targeting the rat HER-2 portion of each 794 
chimeric ORF. The 2,650 bp band (circled in yellow) corresponding to the  non-retargeted pBAC-795 
BoHV-4-A-TK-KanaGalK-TK control is replaced by 2,825 bp, 3,642 bp and 3,464 bp bands (circled in 796 
red) in pBAC-BoHV-4-RRT-gD, pBAC-BoHV-4-RHuT-gD and pBAC-BoHV-4-RRT-Fc, respectively. 797 
 798 
Figure 4. Reconstitution and characterization of recombinant viruses. Representative phase contrast 799 
and fluorescent microscopy images of the plaques formed by viable, reconstituted recombinant BoHV-800 
4-RHuT-gD (A), BoHV-4-RRT-Fc (D) and BoHV-4-RRT-gD (G) after electroporation of the 801 
corresponding BAC DNA clones into BEK or BEKcre cells (magnification, ×10). Replication rates of 802 
BoHV-4-RHuT-gD, BoHV-4-RRT-Fc and BoHV-4-RRT-gD grown in BEK cells are shown in panels 803 
B, E and H, respectively, and compared with those of the parental BoHV-4-A isolate. The data the 804 
mean ± standard error of triplicate measurements (P>0.05 for all time-points; Student's t-test). The 805 
results of immunoblotting analyses conducted on extracts from cells infected with BoHV-4-RHuT-gD, 806 
BoHV-4-RRT-Fc and BoHV-4-RRT-gD are shown in panels C, F and I, respectively; BoHV-4-A 807 
infected cells served as negative controls.  808 
 809 
Figure 5. Anti-Her-2-specific immune responses induced by intraperitoneal vaccination with 810 
the different recombinant BoHV-4 viral particles. (A) Sera from BALB/c mice (n=7), collected two 811 
weeks after the second vaccination , analyzed (at a 1:100 dilution) for the presence of specific anti-rat-812 
HerR-2 antibodies by flow cytometry. Results are expressed as mean fluorescence intensity (MFI) 813 
values for each serum; horizontal lines represent median values (***: p<0.0001; Student’s t-test). (B) In 814 
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vivo cytotoxic responses against the H2d dominant, rat Her-2 peptide TYVPANASL measured in mice 815 
immunized with the indicated BoHV-4 viral particles (n=3) two weeks after the second vaccination; 816 
data are mean ± SEM values (***: p=0.0004; Student’s t-test. (C) T-cell responses against the H2d 817 
dominant, rat Her-2 TYVPANASL peptide determined two weeks after the second vaccination by an in 818 
vitro IFN-γ-based ELISPOT assay. IFN-γ-producing cells from mice immunized with the indicated 819 
BoHV-4 viral particles (n=3) are expressed as SFU/1x106 SPC; data are mean ± SEM values (***:, 820 
p<0.0001; Student’s t-test). 821 
 822 
Figure 6. Anti-rat-Her-2 antibody production and delayed mammary tumor appearance 823 
induced by vaccination with BoHV-4-RHuT-gD viral particles. (A) Sera from BALB-neuT mice, 824 
collected two weeks after the first (grey dots; n=8 to 17 animals/group) and the second (black dots; n=7-825 
17 animals/group) i.p. immunization with the indicated BoHV-4 particles, were analyzed by flow 826 
cytometry (at a 1.100 dilution) for the presence of specific anti-rat-Her-2 antibodies. Results are 827 
expressed as mean fluorescence intensity (MFI) values for each serum; horizontal lines represent 828 
median values (***: p<0.0001; Student’s t-test). (B) Mammary tumor incidence in control BoHV-4-829 
A29-gD (dotted gray line, n=8), BoHV-4-RRT-gD, (dotted black line, n=11), BoHV-4-RRT-Fc (solid black 830 
line, n = 11) and BoHV-4-RHuT-gD (solid red line, n=17) BALB-neuT mice vaccinated with the 831 
indicated BoHV-4 viral particles (***: p<0.0001; Mantel-Haenszel Log-rank test). 832 
 833 
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atgatcatcatggagctggcggcctggtgccgctgggggttcctcctcgccctcctgccc 
 M  I  I  M  E  L  A  A  W  C  R  W  G  F  L  L  A  L  L  P  
cccggaatcgcgggcacccaagtgtgtaccggcacagacatgaagttgcggctccctgcc 
 P  G  I  A  G  T  Q  V  C  T  G  T  D  M  K  L  R  L  P  A  
agtcctgagacccacctggacatgctccgccacctgtaccagggctgtcaggtagtgcag 
 S  P  E  T  H  L  D  M  L  R  H  L  Y  Q  G  C  Q  V  V  Q  
ggcaacttggagcttacctacgtgcctgccaatgccagcctctcattcctgcaggacatc 
 G  N  L  E  L  T  Y  V  P  A  N  A  S  L  S  F  L  Q  D  I  
caggaagttcagggttacatgctcatcgctcacaaccaggtgaagcgcgtcccactgcaa 
 Q  E  V  Q  G  Y  M  L  I  A  H  N  Q  V  K  R  V  P  L  Q  
aggctgcgcatcgtgagagggacccagctctttgaggacaagtatgccctggctgtgcta 
 R  L  R  I  V  R  G  T  Q  L  F  E  D  K  Y  A  L  A  V  L  
gacaaccgagatcctcaggacaatgtcgccgcctccaccccaggcagaaccccagagggg 
 D  N  R  D  P  Q  D  N  V  A  A  S  T  P  G  R  T  P  E  G  
ctgcgggagctgcagcttcgaagtctcacagagatcctgaagggaggagttttgatccgt 
 L  R  E  L  Q  L  R  S  L  T  E  I  L  K  G  G  V  L  I  R  
gggaaccctcagctctgctaccaggacatggttttgtggaaggacgtcttccgcaagaat 
 G  N  P  Q  L  C  Y  Q  D  M  V  L  W  K  D  V  F  R  K  N  
aaccaactggctcctgtcgatatagacaccaatcgttcccgggcctgtccaccttgtgcc 
 N  Q  L  A  P  V  D  I  D  T  N  R  S  R  A  C  P  P  C  A  
cccgcctgcaaagacaatcactgttggggtgagagtccggaagactgtcagatcttgact 
 P  A  C  K  D  N  H  C  W  G  E  S  P  E  D  C  Q  I  L  T  
ggcaccatctgtaccagtggttgtgcccggtgcaagggccggctgcccactgactgctgc 
 G  T  I  C  T  S  G  C  A  R  C  K  G  R  L  P  T  D  C  C  
catgagcagtgtgccgcaggctgcacgggccccaagcattctgactgcctggcctgcctc 
 H  E  Q  C  A  A  G  C  T  G  P  K  H  S  D  C  L  A  C  L  
cacttcaatcatagtggtatctgtgagctgcactgcccagccctcgtcacctacaacaca 
 H  F  N  H  S  G  I  C  E  L  H  C  P  A  L  V  T  Y  N  T  
gacacctttgagtccatgcacaaccctgagggtcgctacacctttggtgccagctgcgtg 
 D  T  F  E  S  M  H  N  P  E  G  R  Y  T  F  G  A  S  C  V  
accacctgcccctacaactacctgtctacggaagtgggatcctgcactctggtgtgtccc 
 T  T  C  P  Y  N  Y  L  S  T  E  V  G  S  C  T  L  V  C  P  
ccgaataaccaagaggtcacagctgaggacggaacacagcgttgtgagaaatgcagcaag 
 P  N  N  Q  E  V  T  A  E  D  G  T  Q  R  C  E  K  C  S  K  
ccctgtgctcgagtgtgctatggtctgggcatggagcaccttcgaggggcgagggccatc 
 P  C  A  R  V  C  Y  G  L  G  M  E  H  L  R  G  A  R  A  I  
accagtgacaatgtccaggagtttgatggctgcaagaagatctttgggagcctggcattt 
 T  S  D  N  V  Q  E  F  D  G  C  K  K  I  F  G  S  L  A  F  
ttgccggagagctttgatggggacccctcctccggcattgctccgctgaggcctgagcag 
 L  P  E  S  F  D  G  D  P  S  S  G  I  A  P  L  R  P  E  Q  
ctccaagtgttcgaaaccctggaggagatcacaggttacctatacatctcagcatggccg 
 L  Q  V  F  E  T  L  E  E  I  T  G  Y  L  Y  I  S  A  W  P  
gacagcctgcctgacctcagcgtcttccagaacctgcaagtaatccggggacgaattctg 
 D  S  L  P  D  L  S  V  F  Q  N  L  Q  V  I  R  G  R  I  L  
cacaatggcgcctactcgctgaccctgcaagggctgggcatcagctggctggggctgcgc 
 H  N  G  A  Y  S  L  T  L  Q  G  L  G  I  S  W  L  G  L  R  
tcactgagggaactgggcagtggactggccctcatccaccataacacccacctctgcttc 
 S  L  R  E  L  G  S  G  L  A  L  I  H  H  N  T  H  L  C  F  
gtgcacacggtgccctgggaccagctctttcggaacccgcaccaagctctgctccacact 
 V  H  T  V  P  W  D  Q  L  F  R  N  P  H  Q  A  L  L  H  T  
gccaaccggccagaggacgagtgtgtgggcgagggcctggcctgccaccagctgtgcgcc 
 A  N  R  P  E  D  E  C  V  G  E  G  L  A  C  H  Q  L  C  A  
cgagggcactgctggggtccagggcccacccagtgtgtcaactgcagccagttccttcgg 
 R  G  H  C  W  G  P  G  P  T  Q  C  V  N  C  S  Q  F  L  R  
ggccaggagtgcgtggaggaatgccgagtactgcaggggctccccagggagtatgtgaat 
 G  Q  E  C  V  E  E  C  R  V  L  Q  G  L  P  R  E  Y  V  N  
gccaggcactgtttgccgtgccaccctgagtgtcagccccagaatggctcagtgacctgt 
 A  R  H  C  L  P  C  H  P  E  C  Q  P  Q  N  G  S  V  T  C  
tttggaccggaggctgaccagtgtgtggcctgtgcccactataaggaccctcccttctgc 
 F  G  P  E  A  D  Q  C  V  A  C  A  H  Y  K  D  P  P  F  C  
gtggcccgctgccccagcggtgtgaaacctgacctctcctacatgcccatctggaagttt 
 V  A  R  C  P  S  G  V  K  P  D  L  S  Y  M  P  I  W  K  F  
ccagatgaggagggcgcatgccagccttgccccatcaactgcacccactcctgtgtggac 
 P  D  E  E  G  A  C  Q  P  C  P  I  N  C  T  H  S  C  V  D  
ctggatgacaagggctgccccgccgagcagagagccagccctctgacgtccatcgtctct 
 L  D  D  K  G  C  P  A  E  Q  R  A  S  P  L  T  S  I  V  S  
gcggtggttggcattctgctggtcgtggtcttgggggtggtctttgggatcctcatcaag 
 A  V  V  G  I  L  L  V  V  V  L  G  V  V  F  G  I  L  I  K  
cgacggcagcagaagatccggaaggtcgactactggttcatgcgccacgggggcgtcgtt 
 R  R  Q  Q  K  I  R  K  V  D  Y  W  F  M  R  H  G  G  V  V  
ccgccgtattttgaggagtcgaagggctacgagccgccgcctgccgccgatgggggttcc 
 P  P  Y  F  E  E  S  K  G  Y  E  P  P  P  A  A  D  G  G  S  
ccctaa 
 P  -   
 
 
Supplementary Figure 1. Diagram (not to scale), nucleotide and deduced polypeptide sequence of the 
RHuT-gD chimeric protein/ORF. The rat and the human portions are highlighted in yellow and grey, 
respectively;  the gD106 tag is highlighted in red. 
 
     
 
atgatcatcatggagctggcggcctggtgccgctgggggttcctcctcgccctcctgccc 
 M  I  I  M  E  L  A  A  W  C  R  W  G  F  L  L  A  L  L  P  
cccggaatcgcgggcacccaagtgtgtaccggcacagacatgaagttgcggctccctgcc 
 P  G  I  A  G  T  Q  V  C  T  G  T  D  M  K  L  R  L  P  A  
agtcctgagacccacctggacatgctccgccacctgtaccagggctgtcaggtagtgcag 
 S  P  E  T  H  L  D  M  L  R  H  L  Y  Q  G  C  Q  V  V  Q  
ggcaacttggagcttacctacgtgcctgccaatgccagcctctcattcctgcaggacatc 
 G  N  L  E  L  T  Y  V  P  A  N  A  S  L  S  F  L  Q  D  I  
caggaagttcagggttacatgctcatcgctcacaaccaggtgaagcgcgtcccactgcaa 
 Q  E  V  Q  G  Y  M  L  I  A  H  N  Q  V  K  R  V  P  L  Q  
aggctgcgcatcgtgagagggacccagctctttgaggacaagtatgccctggctgtgcta 
 R  L  R  I  V  R  G  T  Q  L  F  E  D  K  Y  A  L  A  V  L  
gacaaccgagatcctcaggacaatgtcgccgcctccaccccaggcagaaccccagagggg 
 D  N  R  D  P  Q  D  N  V  A  A  S  T  P  G  R  T  P  E  G  
ctgcgggagctgcagcttcgaagtctcacagagatcctgaagggaggagttttgatccgt 
 L  R  E  L  Q  L  R  S  L  T  E  I  L  K  G  G  V  L  I  R  
gggaaccctcagctctgctaccaggacatggttttgtggaaggacgtcttccgcaagaat 
 G  N  P  Q  L  C  Y  Q  D  M  V  L  W  K  D  V  F  R  K  N  
aaccaactggctcctgtcgatatagacaccaatcgttcccgggcctgtccaccttgtgcc 
 N  Q  L  A  P  V  D  I  D  T  N  R  S  R  A  C  P  P  C  A  
cccgcctgcaaagacaatcactgttggggtgagagtccggaagactgtcagatcttgact 
 P  A  C  K  D  N  H  C  W  G  E  S  P  E  D  C  Q  I  L  T  
ggcaccatctgtaccagtggttgtgcccggtgcaagggccggctgcccactgactgctgc 
 G  T  I  C  T  S  G  C  A  R  C  K  G  R  L  P  T  D  C  C  
catgagcagtgtgccgcaggctgcacgggccccaagcattctgactgcctggcctgcctc 
 H  E  Q  C  A  A  G  C  T  G  P  K  H  S  D  C  L  A  C  L  
cacttcaatcatagtggtatctgtgagctgcactgcccagccctcgtcacctacaacaca 
 H  F  N  H  S  G  I  C  E  L  H  C  P  A  L  V  T  Y  N  T  
gacacctttgagtccatgcacaaccctgagggtcgctacacctttggtgccagctgcgtg 
 D  T  F  E  S  M  H  N  P  E  G  R  Y  T  F  G  A  S  C  V  
accacctgcccctacaactacctgtctacggaagtgggatcctgcactctggtgtgtccc 
 T  T  C  P  Y  N  Y  L  S  T  E  V  G  S  C  T  L  V  C  P  
ccgaataaccaagaggtcacagctgaggacggaacacagcgttgtgagaaatgcagcaag 
 P  N  N  Q  E  V  T  A  E  D  G  T  Q  R  C  E  K  C  S  K  
ccctgtgctcgagtgtgctatggtctgggcatggagcaccttcgaggggcgagggccatc 
 P  C  A  R  V  C  Y  G  L  G  M  E  H  L  R  G  A  R  A  I  
accagtgacaatgtccaggagtttgatggctgcaagaagatctttgggagcctggcattt 
 T  S  D  N  V  Q  E  F  D  G  C  K  K  I  F  G  S  L  A  F  
ttgccggagagctttgatggggacccctcctccggcattgctccgctgaggcctgagcag 
 L  P  E  S  F  D  G  D  P  S  S  G  I  A  P  L  R  P  E  Q  
ctccaagtgttcgaaaccctggaggagatcacagtcgactactggttcatgcgccacggg 
 L  Q  V  F  E  T  L  E  E  I  T  V  D  Y  W  F  M  R  H  G  
ggcgtcgttccgccgtattttgaggagtcgaagggctacgagccgccgcctgccgccgat 
 G  V  V  P  P  Y  F  E  E  S  K  G  Y  E  P  P  P  A  A  D  
gggggttccccctaa 
 G  G  S  P  -   
 
Supplementary Figure 2. Diagram (not to scale), nucleotide and deduced polypeptide sequence of the 
RRT-gD chimeric protein/ORF. The rat HER-2 and the gD106 tag portions are highlighted in yellow 
and red, respectively. 
 
  
atgatcatcatggagctggcggcctggtgccgctgggggttcctcctcgccctcctgccc 
 M  I  I  M  E  L  A  A  W  C  R  W  G  F  L  L  A  L  L  P  
cccggaatcgcgggcacccaagtgtgtaccggcacagacatgaagttgcggctccctgcc 
 P  G  I  A  G  T  Q  V  C  T  G  T  D  M  K  L  R  L  P  A  
agtcctgagacccacctggacatgctccgccacctgtaccagggctgtcaggtagtgcag 
 S  P  E  T  H  L  D  M  L  R  H  L  Y  Q  G  C  Q  V  V  Q  
ggcaacttggagcttacctacgtgcctgccaatgccagcctctcattcctgcaggacatc 
 G  N  L  E  L  T  Y  V  P  A  N  A  S  L  S  F  L  Q  D  I  
caggaagttcagggttacatgctcatcgctcacaaccaggtgaagcgcgtcccactgcaa 
 Q  E  V  Q  G  Y  M  L  I  A  H  N  Q  V  K  R  V  P  L  Q  
aggctgcgcatcgtgagagggacccagctctttgaggacaagtatgccctggctgtgcta 
 R  L  R  I  V  R  G  T  Q  L  F  E  D  K  Y  A  L  A  V  L  
gacaaccgagatcctcaggacaatgtcgccgcctccaccccaggcagaaccccagagggg 
 D  N  R  D  P  Q  D  N  V  A  A  S  T  P  G  R  T  P  E  G  
ctgcgggagctgcagcttcgaagtctcacagagatcctgaagggaggagttttgatccgt 
 L  R  E  L  Q  L  R  S  L  T  E  I  L  K  G  G  V  L  I  R  
gggaaccctcagctctgctaccaggacatggttttgtggaaggacgtcttccgcaagaat 
 G  N  P  Q  L  C  Y  Q  D  M  V  L  W  K  D  V  F  R  K  N  
aaccaactggctcctgtcgatatagacaccaatcgttcccgggcctgtccaccttgtgcc 
 N  Q  L  A  P  V  D  I  D  T  N  R  S  R  A  C  P  P  C  A  
cccgcctgcaaagacaatcactgttggggtgagagtccggaagactgtcagatcttgact 
 P  A  C  K  D  N  H  C  W  G  E  S  P  E  D  C  Q  I  L  T  
ggcaccatctgtaccagtggttgtgcccggtgcaagggccggctgcccactgactgctgc 
 G  T  I  C  T  S  G  C  A  R  C  K  G  R  L  P  T  D  C  C  
catgagcagtgtgccgcaggctgcacgggccccaagcattctgactgcctggcctgcctc 
 H  E  Q  C  A  A  G  C  T  G  P  K  H  S  D  C  L  A  C  L  
cacttcaatcatagtggtatctgtgagctgcactgcccagccctcgtcacctacaacaca 
 H  F  N  H  S  G  I  C  E  L  H  C  P  A  L  V  T  Y  N  T  
gacacctttgagtccatgcacaaccctgagggtcgctacacctttggtgccagctgcgtg 
 D  T  F  E  S  M  H  N  P  E  G  R  Y  T  F  G  A  S  C  V  
accacctgcccctacaactacctgtctacggaagtgggatcctgcactctggtgtgtccc 
 T  T  C  P  Y  N  Y  L  S  T  E  V  G  S  C  T  L  V  C  P  
ccgaataaccaagaggtcacagctgaggacggaacacagcgttgtgagaaatgcagcaag 
 P  N  N  Q  E  V  T  A  E  D  G  T  Q  R  C  E  K  C  S  K  
ccctgtgctcgagtgtgctatggtctgggcatggagcaccttcgaggggcgagggccatc 
 P  C  A  R  V  C  Y  G  L  G  M  E  H  L  R  G  A  R  A  I  
accagtgacaatgtccaggagtttgatggctgcaagaagatctttgggagcctggcattt 
 T  S  D  N  V  Q  E  F  D  G  C  K  K  I  F  G  S  L  A  F  
ttgccggagagctttgatggggacccctcctccggcattgctccgctgaggcctgagcag 
 L  P  E  S  F  D  G  D  P  S  S  G  I  A  P  L  R  P  E  Q  
ctccaagtgttcgaaaccctggaggagatcacagtcgaccgtacgcggccgctcgagccc 
 L  Q  V  F  E  T  L  E  E  I  T  V  D  R  T  R  P  L  E  P  
agagggcccacaatcaagccctgtcctccatgcaaatgcccagcacctaacctcttgggt 
 R  G  P  T  I  K  P  C  P  P  C  K  C  P  A  P  N  L  L  G  
ggaccatccgtcttcatcttccctccaaagatcaaggatgtactcatgatctccctgagc 
 G  P  S  V  F  I  F  P  P  K  I  K  D  V  L  M  I  S  L  S  
cccatagtcacatgtgtggtggtggatgtgagcgaggatgacccagatgtccagatcagc 
 P  I  V  T  C  V  V  V  D  V  S  E  D  D  P  D  V  Q  I  S  
tggtttgtgaacaacgtggaagtacacacagctcagacacaaacccatagagaggattac 
 W  F  V  N  N  V  E  V  H  T  A  Q  T  Q  T  H  R  E  D  Y  
aacagtactctccgggtggtcagtgccctccccatccagcaccaggactggatgagtggc 
 N  S  T  L  R  V  V  S  A  L  P  I  Q  H  Q  D  W  M  S  G  
aaggagttcaaatgcaaggtcaacaacaaagacctcccagcgcccatcgagagaaccatc 
 K  E  F  K  C  K  V  N  N  K  D  L  P  A  P  I  E  R  T  I  
tcaaaacccaaagggtcagtaagagctccacaggtatatgtcttgcctccaccagaagaa 
 S  K  P  K  G  S  V  R  A  P  Q  V  Y  V  L  P  P  P  E  E  
gagatgactaagaaacaggtcactctgacctgcatggtcacagacttcatgcctgaagac 
 E  M  T  K  K  Q  V  T  L  T  C  M  V  T  D  F  M  P  E  D  
atttacgtggagtggaccaacaacgggaaaacagagctaaactacaagaacactgaacca 
 I  Y  V  E  W  T  N  N  G  K  T  E  L  N  Y  K  N  T  E  P  
gtcctggactctgatggttcttacttcatgtacagcaagctgagagtggaaaagaagaac 
 V  L  D  S  D  G  S  Y  F  M  Y  S  K  L  R  V  E  K  K  N  
tgggtggaaagaaatagctactcctgttcagtggtccacgagggtctgcacaatcaccac 
 W  V  E  R  N  S  Y  S  C  S  V  V  H  E  G  L  H  N  H  H  
acgactaagagcttctcccggactccgggtaaatga 
 T  T  K  S  F  S  R  T  P  G  K  -   
 
Supplementary Figure 3. Diagram (not to scale), nucleotide and deduced polypeptide sequence of the 
RRT-Fc chimeric protein/ORF. The rat HER-2 and the Fc portions are highlighted in yellow and grey, 
respectively. 
 
  
 
Supplementary Figure 4. Anti-rat-Her-2-specific antibodies elicited by i.p. vaccination of rat-HER-2-
tolerant mice with the indicated recombinant pINT2 plasmids. Sera from BALB-neuT mice (n=7), 
collected two weeks after the first (grey dots) and the second (black dots) vaccination, were analyzed (at a 
1:100 dilution) for the presence of specific anti-rat-Her-2 antibodies by flow cytometry. Results are 
expressed as mean fluorescence intensity (MFI) values for each serum; horizontal lines represent 
median values (***: p=0.0002; Student’s t-test). 
 
          
 
 
 
 
Supplementary Figure 5. Stability of the pBAC-BoHV-4-RHuT-gD, pBAC-BoHV-4-RRT-gD and 
pBAC-BoHV-4-RRT-gD  plasmids after multiple passages (up to 20) in E. coli SW102 cells. 
  
 
 
 
Supplementary figure 6. RHuT expressed on the cell surface of BoHV-4-RHuT-gD infected murine 
mammary epithelial cells is recognized by an anti rat-Her-2 monoclonal antibody. Cytofluorimetric (A) 
and immunofluorescence (B) staining of Nmug cells 24 hours after live (middle panels) and heat 
inactivated (lower panels) BoHV-4-RHuT-gD infection. 
 
